Retatrutide Cost and Insurance: What to Expect When It Reaches the Market
Bottom line: No commercial price exists yet — retatrutide is not FDA approved. Analyst projections suggest $800–$1,500 per month at list price, consistent with other GLP-1 drugs. Insurance coverage will depend on the approved indication and formulary decisions made after approval.
Quick Answers
How much will retatrutide cost in the United States?
No commercial price has been announced. Eli Lilly has not disclosed pricing for retatrutide. Based on comparable approved GLP-1/GIP drugs — semaglutide (Wegovy) at approximately $900–$1,000/month and tirzepatide (Zepbound) at approximately $1,000–$1,400/month — analysts project a list price of $800–$1,500 per month. These are projections, not confirmed figures.
Actual cost will depend on the approved indication, insurance formulary placement, and any manufacturer savings programs. Eli Lilly has offered savings cards for Zepbound and Mounjaro; a similar program for retatrutide is expected post-approval. See the availability timeline for the expected approval window.
What is the retatrutide price without insurance?
No approved price exists. If retatrutide follows the pricing pattern of comparable GLP-1 drugs, the list price without insurance could be $800–$1,500 per month. Manufacturer savings programs — similar to Eli Lilly's Zepbound Savings Card — are expected post-approval but have not been announced. The only current way to access retatrutide at no cost is through an authorized clinical trial.
For comparison: FDA-approved weight-loss alternatives that are currently available and covered by insurance.
Is retatrutide covered by insurance?
Retatrutide is not yet FDA-approved, so no insurance plan covers it. After approval, coverage will depend on the approved indication, formulary decisions by individual insurers, and whether the drug is classified primarily as a diabetes medication or an obesity medication — a distinction that significantly affects coverage rates across Medicare, Medicaid, and commercial plans.
The insurance landscape for GLP-1 drugs is evolving rapidly. See the full insurance section below for a breakdown of Medicare, commercial, and employer plan coverage patterns. For the regulatory pathway that determines when coverage decisions begin: FDA Regulatory Status.
Key Projections at a Glance
Why There Is No Price Yet
Retatrutide is an investigational drug in Phase 3 clinical trials. It has not received FDA approval and is not commercially available. No list price, wholesale acquisition cost (WAC), or insurance formulary placement exists. Any figure cited as a current price for retatrutide is either fabricated or refers to an illicit product.
Pricing for a new drug is set by the manufacturer at the time of FDA approval and commercial launch. Eli Lilly has not announced a price for retatrutide. The figures on this page are analyst projections based on the pricing of comparable approved GLP-1 drugs and Lilly's historical pricing patterns.
Comparable Drug Pricing: The Reference Points
The most relevant pricing benchmarks are semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) — the two approved GLP-1/GIP drugs with the closest mechanism and efficacy profile to retatrutide. List prices for these drugs range from approximately $935 to $1,350 per month before insurance or savings programs.
Analyst projections for retatrutide cluster in the $800–$1,500 per month range. The lower end reflects competitive pressure from tirzepatide; the upper end reflects retatrutide's potentially superior efficacy data. Lilly may price at a premium if Phase 3 results demonstrate meaningfully greater weight loss than existing options.
| Drug | Indication | List price | Insurance coverage |
|---|---|---|---|
| Semaglutide (Wegovy) | Obesity | ~$1,350/mo | Variable — many plans exclude |
| Tirzepatide (Zepbound) | Obesity | ~$1,060/mo | Variable — many plans exclude |
| Tirzepatide (Mounjaro) | Type 2 diabetes | ~$1,060/mo | Broader — T2D indication |
| Semaglutide (Ozempic) | Type 2 diabetes | ~$935/mo | Broader — T2D indication |
| Retatrutide (projected) | TBD at approval | $800–$1,500/mo (est.) | Unknown — not yet approved |
Insurance Coverage: What to Expect
Insurance coverage for GLP-1 drugs has been inconsistent and highly variable. Coverage depends on the approved indication, the formulary tier assigned by each plan, and prior authorization requirements. Drugs approved for type 2 diabetes have historically received broader coverage than those approved for obesity only.
CMS established the Medicare GLP-1 Bridge demonstration, which began July 1, 2026 and runs through December 31, 2027 unless subsequently changed. It provides access to certain GLP-1 medications for eligible Medicare beneficiaries under the demonstration's rules — it is not universal Medicare coverage of all obesity drugs. Retatrutide itself remains investigational and is not currently an FDA-approved commercial obesity medication, so it is not covered under any Medicare program. Commercial insurance coverage will vary by plan and employer. Many large employers have excluded GLP-1 obesity drugs from coverage due to cost; this landscape may shift by the time retatrutide reaches the market.
Prior authorization requirements are common for GLP-1 drugs. Plans typically require documentation of BMI, comorbidities, and prior weight-loss attempts. Step therapy requirements — requiring patients to try and fail on lower-cost alternatives first — are also common.
Access Pathways: What Will Be Available
Several access pathways are expected to be available after retatrutide receives FDA approval, based on Eli Lilly's established pattern with its other GLP-1 drugs. The only pathway available today is participation in an authorized clinical trial.
Access retatrutide at no cost today
Authorized clinical trials provide pharmaceutical-grade retatrutide free of charge, under medical supervision, at licensed research sites across the US. No insurance required.
How to find a retatrutide clinical trial →Frequently Asked Questions
How much will retatrutide cost per month in the United States?
No commercial price exists yet. Based on comparable GLP-1/GIP drugs (tirzepatide at $1,000–$1,400/month, semaglutide at $900–$1,000/month), analysts project a list price of $800–$1,500 per month. Actual out-of-pocket costs will depend on insurance coverage, manufacturer savings programs, and formulary placement.
What is the retatrutide price without insurance?
No approved price exists. If retatrutide follows the pricing pattern of comparable GLP-1 drugs, the list price without insurance could be $800–$1,500 per month. Eli Lilly has not announced pricing. Manufacturer savings programs, similar to those offered for Zepbound and Mounjaro, are expected post-approval but have not been announced.
Will Medicare cover retatrutide?
Retatrutide remains investigational and is not currently FDA-approved, so it is not covered by any Medicare program. CMS established the Medicare GLP-1 Bridge demonstration, which began July 1, 2026 and runs through December 31, 2027 unless subsequently changed. It provides access to certain GLP-1 medications for eligible Medicare beneficiaries under the demonstration's rules — it is not universal Medicare coverage of all obesity drugs. If retatrutide is eventually approved and added to Part D formularies, coverage will depend on the approved indication and individual plan decisions.
Will commercial insurance cover retatrutide?
Coverage will vary by plan. Many commercial plans cover GLP-1 drugs for type 2 diabetes but exclude them for obesity. Formulary placement and prior authorization requirements will determine patient cost-sharing. Employer-sponsored plans have been inconsistent in covering obesity medications.
Will Eli Lilly offer a patient savings program for retatrutide?
Eli Lilly has offered savings programs for its other GLP-1 drugs (Zepbound Savings Card, Mounjaro Savings Card). A similar program for retatrutide is expected after approval, but no program has been announced as of September 2026.
Can I get retatrutide for free right now?
Yes — through an authorized clinical trial. Participants in registered Phase 3 trials receive pharmaceutical-grade retatrutide at no cost, under medical supervision. This is the only legal way to access retatrutide today.
Will retatrutide be cheaper than tirzepatide or semaglutide?
Unlikely at launch. Novel branded GLP-1 drugs have launched at similar price points. Generic or biosimilar competition, which could reduce prices significantly, is years away from retatrutide given its current investigational status.
Is retatrutide covered by insurance?
Retatrutide is not yet FDA-approved, so no insurance plan covers it. After approval, coverage will depend on the approved indication, formulary decisions by individual insurers, and whether the drug is classified as a diabetes medication or an obesity medication — a distinction that significantly affects coverage rates.